K. Sheares (Cambridge, United Kingdom), C.A Elliot (Sheffield, United Kingdom)
Experience with inhaled iloprost in paediatric pulmonary arterial hypertension
A. Torrent Vernetta, A. Moreno Galdó, I. Mir Messa, S. Rovira Amigó, J. Girona Comas, S. Gartner, M. T. Benabides Medina, C. Martin de Vicente (Barcelona, Spain)
|   |
Sildenafil (SIL) reduces serum creatinine (SCr) in patients with pulmonary arterial hypertension (PAH): Relationship to clinical outcomes
D. Webb, J. L. Vachiery, L. J. Hwang, S. Watt, J. Maurey (Edinburgh, United Kingdom; Brussels, Belgium; New York, United States Of America)
| |
Epoprostenol with expanded stability has the same pharmacokinetic and hemodynamic profiles as epoprostenol in healthy subjects
L. Nicolas, M. Gutierrez, L. Galitz, J. Dingemanse (Allschwil, Switzerland; Miami, United States Of America)
| |
Switch from sitaxentan to another ERA in PAH: Single center short term safety observations
T. Lange, M. Arzt, M. Pfeifer (Regensburg, Donaustauf, Germany)
| |
Double combination therapy in patients with pulmonary arterial hypertension associated with congenital heart defects
N. Rizzo, E. Conficoni, M. Palazzini, E. Leci, E. Gotti, G. Mazzanti, F. Terzi, A. Manes, E. Beciani, F. Sciarra, C. Bachetti, F. Sgro‘, N. Galiè (Bologna, Italy)
| |
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
V. Shenoy, A. Gjymishka, K. Rigatto, Y. Qi, C. Bradford, D. Ely, M. Katovich, M. Raizada (Gainesville, United States Of America)
| |
Effect of treatment on exercise endurance tolerance and ventilatory efficiency in patients with pulmonary arterial hypertension (PAH)
D. Martolini, P. Onorati, G. Valli, A. M. Ferrazza, P. Marinelli, M. Internullo, L. Sardo, C. Gambardella, B. Pezzuto, C. D. Vizza, P. Palange (Rome, Italy)
| |
Improved survival in medically-treated chronic thromboembolic pulmonary hypertension
R. Nishimura, N. Tanabe, Y. Ichimura, A. Sekine, T. Sugiura, T. Jujo, A. Shigeta, S. Sakao, Y. Kasahara, Y. Takiguchi, K. Tatsumi (Chiba, Japan)
| |
Biphasic cuirass ventilation decreased the indices of pulmonary circulation in patients with secondary pulmonary hypertension
Y. Sato, T. Asakura, N. Saeki, K. Aoshiba, T. Kotani (Tokyo, Kawasaki, Japan)
| |
Cure pulmonary arterial hypertension associated with HIV (PAH-HIV)? … Toward an answer
C. Tcherakian, E. Rivaud, A. C. Metivier, E. Catherinot, D. Zucman, L. J. Couderc (Suresnes, France)
| |
Effects of BAY 41-8543 and sildenafil on right heart structure and function in pulmonary artery banded mice
W. Janssen, Y. Schymura, A. Wietelmann, J. P. Stasch, H. Luitel, N. Weissmann, H. A. Ghofrani, F. Grimminger, T. Braun, W. Seeger, R. T. Schermuly (Bad Nauheim, Giessen, Wuppertal, Germany)
| |
Comparison of different vasodilators in a model of secondary pulmonary hypertension (PH): Desaturation effects
E. M. Becker, J. P. Stasch, M. Bechem, R. Kast, H. Truebel (Wuppertal, Germany)
| |
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
M. Iglarz, K. Landskroner, D. Wanner, M. Rey, P. Hess, M. Clozel (Allschwil, Switzerland)
| |
First and second line treatment pattern among pulmonary hypertension patients enrolled in a managed care health plan
V. Joish, D. Muccino, C. Krelick (Wayne, United States Of America)
| |
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib
D. Montani, E. Bergot, S. Günther, L. Savale, A. Bergeron, A. Bourdin, H. Bouvaist, M. Canuet, C. Pison, M. Macro, P. Poubeau, D. Natali, F. Perros, D. S. O‘Callaghan, X. Jaïs, G. Zalcman, O. Sitbon, G. Simonneau, M. Humbert (Clamart, Caen, Paris, Montpellier, Grenoble, Strasbourg, Saint-Pierre, Réunion, France)
| |
Everolimus improves exercise capacity and pulmonary vascular resistance in patients with advanced pulmonary hypertension – A pilot study
H. J. Seyfarth, S. Hammerschmidt, M. Halank, P. Neuhaus, H. Wirtz (Leipzig, Dresden, Germany)
| |
Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension
M. Halank, L. Knudsen, H. J. Seyfarth, R. Ewert, B. Wiedemann, M. Kolditz, G. Hoeffken, M. Hoeper (Dresden, Hannover, Leipzig, Greifswald, Germany)
| |
Double combination therapy in patients with pulmonary arterial hypertension associated with connective tissue disease
E. Gotti, E. Leci, A. Manes, M. Palazzini, E. Beciani, E. Conficoni, N. Rizzo, F. Terzi, G. Mazzanti, F. Sciarra, N. Galiè (Bologna, Italy)
| |
Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease
N. Galie, R. Barst, B. Brundage, H. A. Ghofrani, R. Oudiz, G. Simonneau (Bologna, Italy; New York, Bend, Torrance, United States Of America; Giessen, Germany; Clamart, France)
| |